ConductScience.org, home

Paper23944843

Lessons from (S)-6-(1-(6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)ethyl)quinoline (PF-04254644), an inhibitor of receptor tyrosine kinase c-Met with high protein kinase selectivity but broad phosphodiesterase family inhibition leading to myocardial degeneration in rats.

Cui JJ and 12 others. J Med Chem, 2013. Cited by 28 papers, by iCite.

Cite this record

ConductScience Library. Lessons from (S)-6-(1-(6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)ethyl)quinoline (PF-04254644), an inhibitor of receptor tyrosine kinase c-Met with high protein kinase selectivity but broad phosphodiesterase family inhibition leading to myocardial degeneration in rats. Papers, record 23944843. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/23944843

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Lessons from (S)-6-(1-(6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)ethyl)quinoline (PF-04254644), an inhibitor of receptor tyrosine kinase c-Met with high protein kinase selectivity but broad phosphodiesterase family inhibition leading to myocardial degeneration in rats.
PubMed
Journal
J Med Chem
PubMed
Year
2013
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
28
iCite
Relative citation ratio, by iCite
0.83
iCite
Revised in PubMed
2016-11-25
PubMed

Authors13

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Cui JJJ Jean
2Shen HHong
3Tran-Dubé MMichelle
4Nambu MMitchell
5McTigue MMichele
6Grodsky NNeil
7Ryan KKevin
8Yamazaki SShinji
9Aguirre SShirley
10Parker MMax
11Li QQiuhua
12Zou HHelen
13Christensen JJames

Source PubMed

Download CSV of authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
CardiomyopathiesMajor topic
Phosphodiesterase InhibitorsMajor topic
Protein Kinase InhibitorsMajor topic
QuinolinesMajor topic
Receptor Protein-Tyrosine KinasesMajor topic
Animals
Female
Humans
Mice
Mice, Nude
Models, Molecular
Rats

Source PubMed

Download CSV of topics

Cited by14

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 28 citations.

PMIDTitleJournalYearIn PapersSource
41368778Design and Development of [1,2,4]Triazolo[4,3-b][1,2,4]triazines as Potential Anticancer Agents with Genotoxicity and Apoptotic Activity.Med Chem2025https://conductscience.org/library/papers/41368778PubMed
40678487Scaffold and SAR studies on c-MET inhibitors using machine learning approaches.J Pharm Anal2025https://conductscience.org/library/papers/40678487PubMed
40536894Tyrosine-Mediated Static and Dynamic Quenching of a Receptor Tyrosine Kinase Biosensor Reveals Inhibitor Binding Modes and Kinase Conformations.ACS Chem Biol2025https://conductscience.org/library/papers/40536894PubMed
40182503Fluorescence based live cell imaging identifies exon 14 skipped hepatocyte growth factor receptor (MET) degraders.RSC Adv2025https://conductscience.org/library/papers/40182503PubMed
39720556Recent advances in the treatment of non-small cell lung cancer with MET inhibitors.Front Chem2024https://conductscience.org/library/papers/39720556PubMed
39291032Design and Synthesis of c-Met and HDAC Dual Inhibitors for the Treatment of Breast Cancer.ACS Med Chem Lett2024https://conductscience.org/library/papers/39291032PubMed
35897857Syntheses and Applications of 1,2,3-Triazole-Fused Pyrazines and Pyridazines.Molecules2022https://conductscience.org/library/papers/35897857PubMed
34247323Type II c-Met inhibitors: molecular insight into crucial interactions for effective inhibition.Mol Divers2022https://conductscience.org/library/papers/34247323PubMed
32775889Dual Targeting of VEGFR2 and C-Met Kinases via the Design and Synthesis of Substituted 3-(Triazolo-thiadiazin-3-yl)indolin-2-one Derivatives as Angiogenesis Inhibitors.ACS Omega2020https://conductscience.org/library/papers/32775889PubMed
32549194Therapeutic Efficacy of ABN401, a Highly Potent and Selective MET Inhibitor, Based on Diagnostic Biomarker Test in MET-Addicted Cancer.Cancers (Basel)2020https://conductscience.org/library/papers/32549194PubMed
32117981The Function of the HGF/c-Met Axis in Hepatocellular Carcinoma.Front Cell Dev Biol2020https://conductscience.org/library/papers/32117981PubMed
31030415In Vitro Metabolism by Aldehyde Oxidase Leads to Poor Pharmacokinetic Profile in Rats for c-Met Inhibitor MET401.Eur J Drug Metab Pharmacokinet2019https://conductscience.org/library/papers/31030415PubMed
28587113The Therapeutic Targeting of HGF/c-Met Signaling in Hepatocellular Carcinoma: Alternative Approaches.Cancers (Basel)2017https://conductscience.org/library/papers/28587113PubMed
28404966A novel bispecific c-MET/PD-1 antibody with therapeutic potential in solid cancer.Oncotarget2017https://conductscience.org/library/papers/28404966PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/23944843

GET https://conductscience.org/api/papers/v1/23944843/authors